JP2019505485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505485A5 JP2019505485A5 JP2018530075A JP2018530075A JP2019505485A5 JP 2019505485 A5 JP2019505485 A5 JP 2019505485A5 JP 2018530075 A JP2018530075 A JP 2018530075A JP 2018530075 A JP2018530075 A JP 2018530075A JP 2019505485 A5 JP2019505485 A5 JP 2019505485A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- egfr
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 2
- 230000037452 priming Effects 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 102100039788 GTPase NRas Human genes 0.000 claims 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 238000003318 immunodepletion Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022081697A JP7494245B2 (ja) | 2015-12-11 | 2022-05-18 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266470P | 2015-12-11 | 2015-12-11 | |
| US62/266,470 | 2015-12-11 | ||
| US201662380177P | 2016-08-26 | 2016-08-26 | |
| US62/380,177 | 2016-08-26 | ||
| PCT/US2016/065641 WO2017100462A2 (en) | 2015-12-11 | 2016-12-08 | Treatment of cancer with dual targeting of cd47 and egfr |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022081697A Division JP7494245B2 (ja) | 2015-12-11 | 2022-05-18 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505485A JP2019505485A (ja) | 2019-02-28 |
| JP2019505485A5 true JP2019505485A5 (enExample) | 2019-12-05 |
| JP7077226B2 JP7077226B2 (ja) | 2022-05-30 |
Family
ID=59013321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530075A Active JP7077226B2 (ja) | 2015-12-11 | 2016-12-08 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
| JP2022081697A Active JP7494245B2 (ja) | 2015-12-11 | 2022-05-18 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022081697A Active JP7494245B2 (ja) | 2015-12-11 | 2022-05-18 | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10344094B2 (enExample) |
| EP (1) | EP3386545A4 (enExample) |
| JP (2) | JP7077226B2 (enExample) |
| KR (2) | KR20250004896A (enExample) |
| CN (2) | CN108367073A (enExample) |
| AU (3) | AU2016365829B2 (enExample) |
| CA (1) | CA3005911A1 (enExample) |
| WO (1) | WO2017100462A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10568383B2 (en) * | 2015-01-16 | 2020-02-25 | Nike, Inc. | Sole system for an article of footwear incorporating a knitted component with a one-piece knit outsole and a tensile element |
| US9848673B2 (en) | 2015-01-16 | 2017-12-26 | Nike, Inc. | Vacuum formed knit sole system for an article of footwear incorporating a knitted component |
| JP7198083B2 (ja) * | 2015-08-26 | 2022-12-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７遮断及び免疫同時刺激アゴニストを用いた標的細胞の枯渇亢進 |
| CN108367073A (zh) * | 2015-12-11 | 2018-08-03 | 小利兰·斯坦福大学托管委员会 | 以双重靶向cd47和egfr来治疗癌症 |
| EA038880B1 (ru) | 2016-01-11 | 2021-11-01 | Форти Севен, Инк. | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| US10995152B2 (en) | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| KR102776457B1 (ko) * | 2017-10-18 | 2025-03-06 | 포티 세븐, 엘엘씨 | 항-cd47 작용제-기초된 난소암 요법 |
| AR113862A1 (es) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| ES2927305T3 (es) | 2018-02-12 | 2022-11-04 | Forty Seven Inc | Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20 |
| US20210040219A1 (en) * | 2018-03-13 | 2021-02-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by egfr antibody |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| CN110331200A (zh) * | 2019-06-28 | 2019-10-15 | 中山大学附属第六医院 | Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用 |
| WO2021046216A1 (en) * | 2019-09-03 | 2021-03-11 | Arch Oncology, Inc. | Methods for identifying biomarkers to predict treatment response |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| WO2023165618A1 (en) * | 2022-03-04 | 2023-09-07 | Nanjing University | Methods for treating cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| US20130236449A1 (en) * | 2010-04-21 | 2013-09-12 | Ventirx Pharmaceuticals, Inc. | Methods of enhancing antibody-dependent cellular cytotoxicity |
| HRP20170254T1 (hr) | 2010-05-14 | 2017-04-21 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 |
| EA201390575A1 (ru) * | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| US20140134158A1 (en) | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| RU2693078C2 (ru) | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| JP6426693B2 (ja) | 2013-03-15 | 2018-11-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| KR20150130349A (ko) * | 2013-03-15 | 2015-11-23 | 메르크 파텐트 게엠베하 | 4가 이중특이적 항체 |
| WO2014179132A1 (en) * | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-cd47 agents to enhance immunization |
| ES2728668T3 (es) * | 2014-01-08 | 2019-10-28 | Univ Leland Stanford Junior | Terapia dirigida para el cáncer de pulmón de células pequeñas |
| JP6606505B2 (ja) * | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 |
| EP3209769B1 (en) * | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| US20160036232A1 (en) | 2015-10-09 | 2016-02-04 | LT Lighting (Taiwan) Corp. | Maximum energy utilization point tracking technologies |
| CN108367073A (zh) | 2015-12-11 | 2018-08-03 | 小利兰·斯坦福大学托管委员会 | 以双重靶向cd47和egfr来治疗癌症 |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| CN106519036B (zh) * | 2016-11-04 | 2019-06-11 | 新乡医学院 | 抗cd47和egfr的双功能蛋白及其制备方法与应用 |
-
2016
- 2016-12-08 CN CN201680072080.9A patent/CN108367073A/zh active Pending
- 2016-12-08 KR KR1020247039741A patent/KR20250004896A/ko not_active Ceased
- 2016-12-08 CN CN202210862489.8A patent/CN115569192A/zh active Pending
- 2016-12-08 EP EP16873852.4A patent/EP3386545A4/en active Pending
- 2016-12-08 AU AU2016365829A patent/AU2016365829B2/en active Active
- 2016-12-08 KR KR1020187016533A patent/KR102763202B1/ko active Active
- 2016-12-08 US US15/373,150 patent/US10344094B2/en active Active
- 2016-12-08 WO PCT/US2016/065641 patent/WO2017100462A2/en not_active Ceased
- 2016-12-08 CA CA3005911A patent/CA3005911A1/en active Pending
- 2016-12-08 JP JP2018530075A patent/JP7077226B2/ja active Active
-
2019
- 2019-05-14 US US16/411,547 patent/US11130813B2/en active Active
-
2020
- 2020-04-23 AU AU2020202712A patent/AU2020202712B2/en active Active
-
2021
- 2021-08-25 US US17/411,953 patent/US12037402B2/en active Active
-
2022
- 2022-05-18 JP JP2022081697A patent/JP7494245B2/ja active Active
-
2023
- 2023-03-30 AU AU2023201938A patent/AU2023201938B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505485A5 (enExample) | ||
| Jia et al. | EGF816 exerts anticancer effects in non–small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor | |
| ZA202210065B (en) | Interleukin-21 muteins and methods of treatment | |
| JP2015500002A5 (enExample) | ||
| JP2016513640A5 (enExample) | ||
| Sektioglu et al. | Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection | |
| UA108912C2 (uk) | БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α | |
| JP2017537070A5 (enExample) | ||
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| ATE419277T1 (de) | Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| JO3283B1 (ar) | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) | |
| BR112015002272A2 (pt) | tratamento de doenças inflamatórias e imune-relacionadas | |
| MA35208B1 (fr) | Protéines de liaison à bcma (cd269/tnfrsf17) | |
| WO2014031646A3 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| CL2014003637A1 (es) | Anticuerpo monoclonal optimizado que se une al gen 3 de activación de linfocitos (lag-3); molécula biespecífica que lo comprende; inmunoconjugado que comprende el anticuerpo unido a un agente terapéutico; composición; ácido nucleico; vector; célula huésped; método de preparación; y uso para inhibir el crecimiento de un tumor o tratar una infección viral. | |
| IL187321A (en) | Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation | |
| SI2903616T1 (en) | The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease | |
| US20230223105A1 (en) | Mitigation of statistical bias in genetic sampling | |
| Ishitsuka et al. | Cutaneous squamous cell carcinoma in the age of immunotherapy | |
| Rai et al. | The longevity of memory CD8 T cell responses after repetitive antigen stimulations | |
| BR112014027905A2 (pt) | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. | |
| JP2015510882A5 (enExample) | ||
| JP2014523398A5 (enExample) | ||
| EA201491352A1 (ru) | Способ лечения рака груди |